The 10 Most Read Articles of 2019
A look back at the developments and interviews that caught the most attention this year.
A look back at the developments and interviews that caught the most attention this year.
Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.
A study shows secukinumab clears skin lesions faster than ustekinumab in generalized pustular psoriasis, with improved responses observed by week 2.
APAC President Laura Ross, PA-C, shares insights from the RhAPP conference, discussing autoimmune disease, cardiovascular risks, and the importance of interdisciplinary care.
A recent study shows the FDA’s black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths…
Anemia is frequently observed in primary care patients with HF and is linked to worse prognosis and comorbidities, including cancer.
The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New…
Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.
The phase 3b/4 findings from PSORIATYK SCALP suggest that oral deucravacitinib led to significant improvements for patients with scalp psoriasis.
Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.
HCPLive spoke to Rodriguez, MD, MPH, about implementing AI in cardiology care.